RecruitingPhase 2NCT06483659

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Sponsor

Brigham and Women's Hospital

Enrollment

152 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Postoperative Pain

Summary

This is a randomized, double-blinded, placebo-controlled trial to compare the effectiveness of IV oxytocin infusion to placebo on peri-operative opioid consumption and reducing post-operative pain following a minimally invasive hysterectomy under general anesthesia.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

Ages 18-65 years old
ASA category 1-3
Scheduled to undergo minimally invasive hysterectomy
No documented allergy to oxytocin

Exclusion Criteria8

American Society of Anesthesiologists (ASA) group 4 or greater
Age >65 years old
Additional surgical procedures including but not limited to minor laparotomy, omentectomy, cystectomy, vaginectomy, and/or ablation of endometriosis.
Active opioid prescription of the equivalent of oxycodone >10 mg /day
Opioid use disorder, including patients in treatment receiving naltrexone or Suboxone (Buprenorphine-naloxone)
Allergies to any study medication: acetaminophen, celecoxib, ketorolac, fentanyl, hydromorphone, or oxycodone.
Epidural/Regional anesthesia for intra-operative or post-operative pain.
Inability to understand the questionnaires